4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) was the target of a significant increase in short interest in November. As of November 30th, there was short interest totalling 8,520,000 shares, an increase of 8.8% from the November 15th total of 7,830,000 shares. Based on an average daily volume of 894,400 shares, the short-interest ratio is presently 9.5 days.
Several large investors have recently made changes to their positions in FDMT. Assenagon Asset Management S.A. lifted its stake in 4D Molecular Therapeutics by 6.0% in the 2nd quarter. Assenagon Asset Management S.A. now owns 456,267 shares of the company's stock valued at $9,577,000 after purchasing an additional 25,711 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in 4D Molecular Therapeutics by 5,735.7% in the 2nd quarter. Nisa Investment Advisors LLC now owns 96,698 shares of the company's stock valued at $2,030,000 after purchasing an additional 95,041 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in 4D Molecular Therapeutics by 28.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 169,413 shares of the company's stock valued at $3,556,000 after purchasing an additional 38,015 shares during the last quarter. Panagora Asset Management Inc. lifted its stake in 4D Molecular Therapeutics by 247.7% in the 2nd quarter. Panagora Asset Management Inc. now owns 354,857 shares of the company's stock valued at $7,448,000 after purchasing an additional 252,789 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its stake in 4D Molecular Therapeutics by 9.6% in the 2nd quarter. Principal Financial Group Inc. now owns 21,034 shares of the company's stock valued at $442,000 after purchasing an additional 1,849 shares during the last quarter. Institutional investors and hedge funds own 99.27% of the company's stock.
Shares of NASDAQ:FDMT traded down $0.11 on Tuesday, reaching $6.37. 61,096 shares of the company's stock were exchanged, compared to its average volume of 882,185. The company has a fifty day moving average of $8.03 and a 200-day moving average of $14.34. 4D Molecular Therapeutics has a twelve month low of $6.34 and a twelve month high of $36.25. The company has a market capitalization of $294.47 million, a price-to-earnings ratio of -2.26 and a beta of 2.74.
A number of equities analysts have issued reports on FDMT shares. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. Royal Bank of Canada reduced their price target on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an "outperform" rating on the stock in a research report on Thursday, November 14th. Cantor Fitzgerald cut shares of 4D Molecular Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday, September 23rd. Chardan Capital reissued a "buy" rating and set a $39.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. Finally, Leerink Partners reissued an "outperform" rating and set a $36.00 price target (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Thursday, September 19th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, 4D Molecular Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $42.13.
Get Our Latest Report on FDMT
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider 4D Molecular Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.
While 4D Molecular Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.